Knockdown of biglycan expression by RNA interference inhibits the proliferation and invasion of, and induces apoptosis in, the HCT116 colon cancer cell line

Xing,Xiaojing; Gu,Xiaohu; Ma,Tianfei

doi:10.3892/mmr.2015.4383

Knockdown of biglycan expression by RNA interference inhibits the proliferation and invasion of, and induces apoptosis in, the HCT116 colon cancer cell line

Authors:
- Xiaojing Xing
- Xiaohu Gu
- Tianfei Ma
View Affiliations

Affiliations: Cancer Prevention and Treatment Office, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning 110042, P.R. China, Department of Surgical Oncology, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning 110042, P.R. China
Published online on: September 29, 2015 https://doi.org/10.3892/mmr.2015.4383
Pages: 7538-7544

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Biglycan is an important component of the extracellular matrix, and it is also a member of small leucine-rich proteoglycan family. Previous studies indicated that the expression of biglycan was increased in a variety of tumor tissues, including colon cancer. However, the mechanisms underlying its effects in colon cancer remain to be fully elucidated. In the present study, the effects of biglycan knockdown on colon cancer cell proliferation, migration, invasion and apoptosis were investigated. The mRNA expression levels of biglycan in the HCT116 colon cancer cell line were downregulated using RNA interference, and the stably transfected cell line was obtained through G418 screening for subsequent experiments. The results revealed that downregulation of the expression of biglycan suppressed cell proliferation and caused a cell cycle arrest at the G0/G1 phase. The results of the western blot analysis also revealed that the expression levels of cell cycle‑associated proteins, including cyclin A and cyclin D1, were markedly decreased following silencing of biglycan, whereas the expression levels of p21 and p27 were markedly increased compared with that of the short hairpin RNA control group. Furthermore, the decreased expression of biglycan inhibited colon cancer cell migration and invasion, and induced apoptosis. A complete inhibition of the p38 signaling pathway with SB203580 effectively reversed the increase in apoptotic cell numbers induced by biglycan downregulation. Taken together, the results of the present study indicated that biglycan exerts an important role in cell proliferation, migration, invasion and apoptosis in colon cancer, and that biglycan regulates the p38 MAPK signaling pathway by exerting an antiapoptotic effect. Therefore, biglycan may represent a putative target for colon cancer gene therapy.

View Figures

View References

1	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI
2	Cheng H, Zhang L, Cogdell DE, Zheng H, Schetter AJ, Nykter M, Harris CC, Chen K, Hamilton SR and Zhang W: Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PloS One. 6:e177452011. View Article : Google Scholar : PubMed/NCBI
3	Yang L, Parkin DM, Ferlay J, Li L and Chen Y: Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev. 14:243–250. 2005.PubMed/NCBI
4	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
5	Wadhwa S, Embree MC, Bi Y and Young MF: Regulation, regulatory activities and function of biglycan. Crit Rev Eukaryot Gene Expr. 14:301–315. 2004. View Article : Google Scholar
6	Ameye L, Aria D, Jepsen K, Oldberg A, Xu T and Young MF: Abnormal collagen fibrils in tendons of biglycan/fibro-modulin-deficient mice lead to gait impairment, ectopic ossification and osteoarthritis. FASEB J. 16:673–680. 2002. View Article : Google Scholar : PubMed/NCBI
7	Young MF, Bi Y, Ameye L and Chen XD: Biglycan knockout mice: New models for musculoskeletal diseases. Glycoconj J. 19:257–262. 2002. View Article : Google Scholar
8	Nishino R, Honda M, Yamashita T, Takatori H, Minato H, Zen Y, Sasaki M, Takamura H, Horimoto K, Ohta T, et al: Identification of novel candidate tumour marker genes for intrahepatic cholangiocarcinoma. J Hepatol. 49:207–216. 2008. View Article : Google Scholar : PubMed/NCBI
9	Pan S, Cheng L, White JT, Lu W, Utleg AG, Yan X, Urban ND, Drescher CW, Hood L and Lin B: Quantitative proteomics analysis integrated with microarray data reveals that extracellular matrix proteins, catenins and p53 binding protein 1 are important for chemotherapy response in ovarian cancers. OMICS. 13:345–354. 2009. View Article : Google Scholar : PubMed/NCBI
10	Liu Y, Li W, Li X, Tai Y, Lü Q, Yang N and Jiang J: Expression and significance of biglycan in endometrial cancer. Arch Gynecol Obstet. 289:649–655. 2014. View Article : Google Scholar
11	Aprile G, Avellini C, Reni M, Mazzer M, Foltran L, Rossi D, Cereda S, Iaiza E, Fasola G and Piga A: Biglycan expression and clinical outcome in patients with pancreatic adenocarcinoma. Tumour Biol. 34:131–137. 2013. View Article : Google Scholar
12	Hu L, Duan YT, Li JF, Su LP, Yan M, Zhu ZG, Liu BY and Yang QM: Biglycan enhances gastric cancer invasion by activating FAK signaling pathway. Oncotarget. 5:1885–1896. 2014. View Article : Google Scholar : PubMed/NCBI
13	Gu X, Ma Y, Xiao J, Zheng H, Song C, Gong Y and Xing X: Up-regulated biglycan expression correlates with the malignancy in human colorectal cancers. Clin Exp Med. 12:195–199. 2012. View Article : Google Scholar
14	Weber CK, Sommer G, Michl P, Fensterer H, Weimer M, Gansauge F, Leder G, Adler G and Gress TM: Biglycan is overexpressed in pancreatic cancer and induces G1-arrest in pancreatic cancer cell lines. Gastroenterology. 121:657–667. 2001. View Article : Google Scholar : PubMed/NCBI
15	Recktenwald CV, Leisz S, Steven A, Mimura K, Müller A, Wulfänger J, Kiessling R and Seliger B: HER-2/neu-mediated down-regulation of biglycan associated with altered growth properties. J Biol Chem. 287:24320–24329. 2012. View Article : Google Scholar : PubMed/NCBI
16	Makatsori E, Lamari FN, Theocharis AD, Anagnostides S, Hjerpe A, Tsegenidis T and Karamanos NK: Large matrix proteoglycans, versican and perlecan, are expressed and secreted by human leukemic monocytes. Anticancer Res. 23:3303–3309. 2003.PubMed/NCBI
17	Hu L, Duan YT, Li JF, Su LP, Yan M, Zhu ZG, Liu BY and Yang QM: Biglycan enhances gastric cancer invasion by activating FAK signaling pathway. Oncotarget. 5:1885–1896. 2014. View Article : Google Scholar : PubMed/NCBI
18	Xia Z, Dickens M, Raingeaud J, Davis RJ and Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science. 270:1326–1331. 1995. View Article : Google Scholar : PubMed/NCBI
19	Zhu YH, Yang F, Zhang SS, Zeng TT, Xie X and Guan XY: High expression of biglycan is associated with poor prognosis in patients with esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 6:2497–2505. 2013.PubMed/NCBI
20	Wang B, Li GX, Zhang SG, Wang Q, Wen YG, Tang HM, Zhou CZ, Xing AY, Fan JW, Yan DW, et al: Biglycan expression correlates with aggressiveness and poor prognosis of gastric cancer. Exp Biol Med (Maywood). 236:1247–1253. 2011. View Article : Google Scholar
21	Theocharis AD and Karamanos NK: Decreased biglycan expression and differential decorin localization in human abdominal aortic aneurysms. Atherosclerosis. 165:221–230. 2002. View Article : Google Scholar : PubMed/NCBI
22	Gupta GP and Massague J: Cancer metastasis: Building a framework. Cell. 127:679–695. 2006. View Article : Google Scholar : PubMed/NCBI
23	Lu P, Weaver VM and Werb Z: The extracellular matrix: A dynamic niche in cancer progression. J Cell Biol. 196:395–406. 2012. View Article : Google Scholar : PubMed/NCBI
24	Stetler-Stevenson WG, Aznavoorian S and Liotta LA: Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol. 9:541–573. 1993. View Article : Google Scholar : PubMed/NCBI
25	Shimizu-Hirota R, Sasamura H, Kuroda M, Kobayashi E, Hayashi M and Saruta T: Extracellular matrix glycoprotein biglycan enhances vascular smooth muscle cell proliferation and migration. Circ Res. 94:1067–1074. 2004. View Article : Google Scholar : PubMed/NCBI
26	Yamamoto K, Ohga N, Hida Y, Maishi N, Kawamoto T, Kitayama K, Akiyama K, Osawa T, Kondoh M, Matsuda K, et al: Biglycan is a specific marker and an autocrine angiogenic factor of tumour endothelial cells. Br J Cancer. 106:1214–1223. 2012. View Article : Google Scholar : PubMed/NCBI
27	Xing X, Gu X, Ma T and Ye H: Biglycan up-regulated vascular endothelial growth factor (VEGF) expression and promoted angiogenesis in colon cancer. Tumor Biol. 36:1773–1780. 2015. View Article : Google Scholar
28	Wagner EF and Nebreda AR: Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 9:537–549. 2009. View Article : Google Scholar : PubMed/NCBI
29	Babelova A, Moreth K, Tsalastra-Greul W, Zeng-Brouwers J, Eickelberg O, Young MF, Bruckner P, Pfeilschifter J, Schaefer RM, Gröne HJ and Schaefer L: Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors. J Biol Chem. 284:24035–24048. 2009. View Article : Google Scholar : PubMed/NCBI
30	Schaefer L, Babelova A, Kiss E, Hausser HJ, Baliova M, Krzyzankova M, Marsche G, Young MF, Mihalik D, Götte M, et al: The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest. 115:2223–2233. 2005. View Article : Google Scholar : PubMed/NCBI